Menopause

Daré Bioscience Reports First Quarter 2024 Financial Results and Provides Company Update

Conference Call and Webcast Today at 4:30 p.m. ETDevelopment Program Highlights and Anticipated 2024 Milestones Ovaprene® hormone-free monthly intravaginal contraceptive…

6 months ago

ARC Fertility Named Finalist for Two Categories at FemTech World Awards 2024

CUPERTINO, Calif.--(BUSINESS WIRE)--ARC Fertility (ARC), a highly experienced national provider of innovative fertility and family-forming benefits for self-insured employers and…

7 months ago

Daré Bioscience to Host First Quarter 2024 Financial Results and Company Update Conference Call and Webcast on May 14, 2024

SAN DIEGO, May 07, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today…

7 months ago

The Fibroid Foundation Announces National Menstrual Health Awareness Month

May is National Menstrual Health Awareness Month - May 28 is International Menstrual Hygiene DayROCKVILLE, MD / ACCESSWIRE / May…

7 months ago

Daré Bioscience Selected as a Member of ARPA-H Investor Catalyst Hub Spoke Network

Daré joins a nationwide network working to accelerate transformative health solutionsSAN DIEGO, May 02, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience,…

7 months ago

Daré Bioscience Secures $22 Million in Non-Dilutive Strategic Royalty Financing to Advance Phase 3 First-in-Category Women’s Health Product Candidates through Key Catalysts

$22 million of non-dilutive capital at close provides significant capital to achieve objectives Upon achieving a pre-specified return threshold, XOMA…

7 months ago

Daré Bioscience Reports Full Year 2023 Financial Results and Provides Company Update

Conference Call and Webcast Today at 4:30 p.m. ET2023 Highlights and Anticipated 2024 Milestones XACIATO™ (clindamycin phosphate) vaginal gel 2%…

8 months ago

Daré Bioscience to Host Full Year 2023 Financial Results and Company Update Conference Call and Webcast on March 28, 2024

SAN DIEGO, March 21, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that it…

8 months ago

Bone Health Technologies Secures $5 Million in Funding to Transform Osteopenia Care

BHT closes oversubscribed financing round, adds new investors to revolutionize low bone density treatmentsREDWOOD CITY, CA / ACCESSWIRE / March…

9 months ago

Daré Bioscience to Present at the International Society for the Study of Women’s Sexual Health (ISSWSH) Annual Meeting

Data to be presented demonstrate increased frequency of sexual events with Sildenafil Cream, 3.6% use in the Phase 2b RESPOND…

9 months ago